November 2025 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in customizing treatments and ensuring medication safety.
February 2023 in “Reactions Weekly” March 2019 in “Reactions Weekly” 1 citations
,
January 1987 in “Veterinary Dermatology” Topical 0.1% tacrolimus improved a rare ear condition in cats.
3 citations
,
January 2018 in “Archives of Disease in Childhood” Switching to generic tacrolimus was safe, effective, and saved money.
33 citations
,
September 2007 in “Veterinary dermatology” Topical 0.1% tacrolimus significantly improved ear infections in cats.
19 citations
,
April 2019 in “Veterinary dermatology” Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.
1 citations
,
November 2016 in “Journal of dermatological treatment” Oral tacrolimus may be a potential treatment for hair loss that doesn't respond to corticosteroids.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.
January 2026 in “Vestnik dermatologii i venerologii” Tacrolimus ointment is effective for various skin conditions but needs more research for long-term effects.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
Further trials are needed to explore the efficacy of triamcinolone acetonide in dermatology.
35 citations
,
August 2001 in “Journal of Cutaneous Medicine and Surgery” Tacrolimus is effective for various skin conditions with fewer side effects than cyclosporine.
January 2024 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib may be safe and effective for treating certain skin conditions in children.
33 citations
,
May 2001 in “Annals of pharmacotherapy/The annals of pharmacotherapy” Topical tacrolimus is safe and effective for skin conditions, but oral tacrolimus has serious side effects.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
61 citations
,
September 2010 in “Fitoterapia” Extracts from Tridax procumbens L. have strong anti-inflammatory and antioxidant effects and block inflammation-causing enzymes.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
4 citations
,
July 2001 in “Journal of Cutaneous Medicine and Surgery” Tacrolimus is an effective treatment for several skin conditions with fewer side effects than cyclosporine.
22 citations
,
March 2019 in “European Journal of Ophthalmology” Preservative-free latanoprost effectively lowers eye pressure with fewer side effects.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
September 2023 in “International Journal of Applied Pharmaceutics” The formulated gel is a promising treatment for alopecia areata.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
48 citations
,
January 2011 in “International journal of trichology” Intralesional triamcinolone acetonide is the most effective treatment for localized alopecia areata.
June 2017 in “Journal of The American Academy of Dermatology” Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.